Regeneron Pharma Q4 Results Top Estimates - Update

RTTNews | Před 622 dny
Regeneron Pharma Q4 Results Top Estimates - Update

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.

Excluding items, adjusted earnings for the quarter $1.37 billion or $11.86 per share, compared to $1.45 billion or $12.56 per share in the year-ago quarter.

On average, 21 analysts polled by Thomson Reuters expected the company to report earnings of $10.87 per share for the quarter. Analysts' estimates typically exclude special items.

Total revenue for the quarter edged up 1 percent to $3.43 billion from $3.41 billion in the same quarter last year. Excluding Ronapreve, revenue grew 14 percent. Analysts were looking for revenues of $3.29 billion for the quarter.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

read more
Regeneron Pharma Q2 Results Top Estimates - Update

Regeneron Pharma Q2 Results Top Estimates - Update

Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.
RTTNews | Před 441 dny
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
RTTNews | Před 475 dny
Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews | Před 1203 dny
Australian Market Modestly Lower

Australian Market Modestly Lower

The Australian stock market is trading modestly lower on Friday, snapping a three-session winning streak, following the broadly negative cues from Wall Street overnight. The benchmark S&P/ASX 200 is falling below the 9,050 level, with weakness in technology stocks and a mixed performance in most other sectors.
RTTNews | Před 4 minutami
Rally May Stall For Taiwan Stock Market

Rally May Stall For Taiwan Stock Market

The Taiwan stock market has climbed higher in consecutive trading days, advancing more than 850 points or 2.9 percent along the way. The Taiwan Stock Exchange now sits just beneath the 27,650-point plateau although it may run out of steam on Friday.
RTTNews | Před 15 minutami
Singapore Bourse May Extend Thursday's Losses

Singapore Bourse May Extend Thursday's Losses

The Singapore stock market headed south again on Thursday, one day after snapping the five-day losing streak in which it had stumbled almost 120 points or 2.9 percent. The Straits Times Index now rests just beneath the 4,360-point plateau and it may take further damage on Friday.
RTTNews | Před 45 minutami
Malaysia Bourse May Remain Stuck In Neutral

Malaysia Bourse May Remain Stuck In Neutral

The Malaysia stock market has moved higher in two straight sessions, although it has picked up less than a point in that span. The Kuala Lumpur Composite Index now sits just above the 1,610-point plateau and little movement is expected again on Friday.
RTTNews | Před 1 h 15 min